MRK250509P101000
- 0.00
- 0.000.00%
Merck & Co Newsroom
Merck, Amgen Share Losses Contribute To Dow's 133-Point Fall
Dow's 300-Point Drop Led By Losses In Shares Of Merck, NVIDIA Corp.
Merck & Co Unusual Options Activity
Immutep Reports 'Excellent' Median Overall Survival in Efti-Keytruda Combo Trial; Shares Rise
Merck & Co | 10-Q: Q1 2025 Earnings Report
8 Health Care Stocks Whale Activity In Today's Session
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
Organon Drops After Dividend Cut
Express News | Amacathera and Merck Animal Health Announce Collaboration in Animal Health
FDA to Tighten Vaccine Approval Requirements: Reports
Merck & Co Options Spot-On: On April 30th, 55,220 Contracts Were Traded, With 700.89K Open Interest
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $108
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness' Stock Picks With Huge Upside Potential
Express News | Merck & Co Inc : Guggenheim Cuts Target Price to $108 From $115
Honeywell, Sherwin-Williams Co. Share Gains Lead Dow's 232-Point Jump
Express News | Merck & Co: Laboratory Component Is Expected to Be Fully Operational by 2028, With Production of Investigational Compounds to Start by 2030
Express News | Merck & Co Inc: Merck Wilmington Biotech Will Serve as a Launch and Commercial Production Facility and Future U.S. Home for Keytruda
Express News | Merck & Co Inc - New Facility to Create 500 Full-Time Roles and 4,000 Jobs
Express News | Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
Merck (MRK.US) plans to invest 1 billion USD to build a factory in the USA to ensure the supply of Keytruda is protected from tariff impacts.
Merck will invest 1 billion dollars to build a factory in Delaware to ensure the domestic supply of Keytruda.